|
|
|
|
LEADER |
01101nam a2200253 u 4500 |
001 |
EB002010719 |
003 |
EBX01000000000000001173618 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
220201 r ||| eng |
100 |
1 |
|
|a Banerjee, Srabani
|
245 |
0 |
0 |
|a PCSK-9 inhibitors for hyperlipidemia
|h Elektronische Ressource
|b a review of the comparative clinical effectiveness
|c Srabani Banerjee, Charlotte Wells, Aleksandra Grobelna
|
260 |
|
|
|a Ottawa
|b CADTH
|c 2017, June 6, 2017
|
300 |
|
|
|a 1 PDF file (21 pages)
|b illustrations
|
505 |
0 |
|
|a Includes bibliographical references
|
700 |
1 |
|
|a Wells, Charlotte
|e [author]
|
700 |
1 |
|
|a Grobelna, Aleksandra
|e [author]
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK524911
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a Alirocumab and evolocumab are expensive drugs (annual cost per patient > Can
|